Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FREDERICK, MD, March 19, 2018 -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. Currently there are 700,000 total knee replacement surgeries in the US alone and are projected to grow 673% to 3.5 million procedures per year by 2030.
Knee Arthroplasty (knee replacement) generally occurs due to degenerative osteoarthritis in the knee joint. While the procedure is common, managing post-operative and long-term pain can be challenging owing to hypersensitivity of nerves in the knee. This nerve hypersensitivity is known as central sensitization and develops over many years due to the underlying osteoarthritis. Disrupting abnormal pain signaling in the nerves is key to reducing the hypersensitivity and providing lasting pain relief. In case studies, RecoveryRx® has shown to be of great clinical value with regards to postoperative pain management and improving long term pain management in subjects undergoing total knee replacement.
The clinical study will involve 40 subjects who are already scheduled for a knee replacement. Each subject will be randomly assigned to receive an active device or placebo device. Enrollment into the study has been initiated, and the study is expected to be completed in December 2018. Full details can be viewed on the clinicaltrials.gov website (NCT03395444). The study is being conducted at the New Mazloum Hospital, Tripoli, Lebanon. Dr. Omar Tabbouche, our distributor in Lebanon, is managing the study and is aggressively introducing BioElectronics’ innovative medical devices into the Lebanese healthcare marketplace.
“RecoveryRx technology has already been shown to reduce knee osteoarthritis pain, so we are confident that this study will demonstrate the clinical efficacy of the device. Additionally, this study will help us gain regulatory clearance and allow for marketing as the standard of care following joint replacement surgeries,” said Dr. Ian Rawe, Ph.D., Director of clinical Research at BioElectronics.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
Paul Knopick 9402623584 [email protected]
